SpectraCure ABOSTO:SPEC +10.38% Return-on-Tangible-Equity is -257.10% as of Mar. 2026. The stock has 1 warning sign investors should review. Among 758 Medical Devices & Instruments companies, SpectraCure AB ranks worse than 96.44% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. SpectraCure AB's annualized net income for the quarter that ended in Mar. 2026 was kr-24.56 Mil. SpectraCure AB's average shareholder tangible equity for the quarter that ended in Mar. 2026 was kr9.55 Mil. Therefore, SpectraCure AB's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was -257.10%.
The historical rank and industry rank for SpectraCure AB's Return-on-Tangible-Equity or its related term are showing as below:
OSTO:SPEC'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -512.93 Med: -35.88 Max: -15.09
Current: -358.53
During the past 12 years, SpectraCure AB's highest Return-on-Tangible-Equity was -15.09%. The lowest was -512.93%. And the median was -35.88%.
OSTO:SPEC's Return-on-Tangible-Equity is ranked worse than 96.44% of 758
companies
in the Medical Devices & Instruments industry
Industry Median: 4.08
vs OSTO:SPEC: -358.53
SpectraCure AB (OSTO:SPEC) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
SpectraCure AB Return-on-Tangible-Equity Related Terms
SpectraCure AB Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for SpectraCure AB's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:SPEC vs ABT, SYK, MDT: Return-on-Tangible-Equity Comparison
For the Medical Devices subindustry, SpectraCure AB's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SpectraCure AB Return-on-Tangible-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, SpectraCure AB's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where SpectraCure AB's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of -257.10% mean?
SpectraCure AB (OSTO:SPEC) has a Return-on-Tangible-Equity of -257.10% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on SpectraCure AB and its competitors. According to the industry distribution chart, SpectraCure AB ranks #731 out of 758 companies in the Medical Devices & Instruments industry, placing it in the top 96.4%.
Is SpectraCure AB's Return-on-Tangible-Equity too high?
SpectraCure AB's current Return-on-Tangible-Equity is -257.10%. Based on the distribution chart, SpectraCure AB ranks #731 out of 758 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers.
How does SpectraCure AB's Return-on-Tangible-Equity compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, SpectraCure AB ranks #731 out of 758 companies for Return-on-Tangible-Equity. This places SpectraCure AB in the lower half of its industry. The industry median Return-on-Tangible-Equity is 4.08. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Devices & Instruments company?
The median Return-on-Tangible-Equity among Medical Devices & Instruments companies is 4.08, based on 758 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on SpectraCure AB and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Equity is 4.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SpectraCure AB's current Return-on-Tangible-Equity is -257.10%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SpectraCure AB stock overvalued right now?
SpectraCure AB (OSTO:SPEC) has a current Return-on-Tangible-Equity of -257.10%. The current Return-on-Tangible-Equity is -257.10%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For SpectraCure AB (OSTO:SPEC), the current Return-on-Tangible-Equity is -257.10% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
SpectraCure AB develops treatment planning and laser light dose management for cancer treatment. The Company has developed its software IDOSE, and medical laser devices for the treatment.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:SPEC has been successfully added to your 